Abatacept Recombinant
Myelodysplastic Syndrome With Excess Blasts-1
Explore 12 assets in Myelodysplastic Syndrome With Excess Blasts-1 →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Boston Children's Hospital
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01012492CT.gov Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myelodysplastic Syndrome With Excess Blasts-1
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Abatacept Recombinant (this asset) | Boston Children's Hospital | P2 | B · 57 |
| Cyclosporin A | Singapore Eye Research Institute | P4 | B |
| Cyclophosphamide | Masonic Cancer Center, University of Minnesota | P2 | B |
| Thiotepa | Fred Hutchinson Cancer Center | P2 | B |
| Fludarabine | Masonic Cancer Center, University of Minnesota | P2 | B |
| Busulfanum | Fred Hutchinson Cancer Center | P2 | B |
| Tacrolimus | Fred Hutchinson Cancer Center | P2 | B |
| Methotrexate | Fred Hutchinson Cancer Center | P2 | B |
| Azacitidine | National Cancer Institute (NCI) | P2 | CCC |
+5 more in the Myelodysplastic Syndrome With Excess Blasts-1 cohort
Other indications for Abatacept Recombinant
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | — | P3 | BB · 68 |
| Primary Biliary Cholangitis | — | P4 | BB · 66 |
| Acute Biphenotypic Leukemia | — | P3 | B · 63 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Abatacept Recombinant in Myelodysplastic Syndrome With Excess Blasts-1. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/abatacept-recombinant-myelodysplastic-syndrome-with-excess-blasts-1
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →